Remove Clinical Development Remove Production Remove Small Molecule
article thumbnail

The rising impact of biomarkers in early clinical development

Drug Target Review

Investigational products with novel mechanisms of action are also assessed for safety in unique ways, creating complexities that can be more dynamically and effectively monitored using biologically relevant biomarkers. Biomarkers can play a crucial role throughout clinical development, especially in early phases.

article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Unimodality does not allow for mixing data: cell data, images, molecular data, clinical data records, small molecule descriptors, ADME Tox data, transcriptomic data, text-based drug and disease representations, clinical trial protocols, publications and patent data, etc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

Over the years, the collaboration has matured into one of the most productive academic-pharma partnerships in China. The company currently operates two global research and development (R&D) centers and four world-class production facilities across China.

article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

Expertise that accelerates your clinical development success The PPD clinical research business of Thermo Fisher Scientific has significant experience in customized Phase I-IV metabolic clinical trials. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.

article thumbnail

Deconstructing the Diligence Process: An Approach to Vetting New Product Theses

LifeSciVC

Additionally, for illustrative reasons this is geared towards a single target / product focus vs. broader platform diligence, though many of these mental models will apply for selecting targets and indications for a platform. and whether a molecule’s pharmacology can help to mitigate safety risk. in liver, in CNS)?

article thumbnail

Metabolism of 2023 FDA Approved Small Molecules – PART 1

Metabolite Tales Blog

Metabolism of 2023 FDA Approved Small Molecules – PART 1 By Julia Shanu-Wilson 2023 was a fruitful year for drug approvals by the FDA, with a crop of 34 small molecules out of a total of 55 new drugs [1]. References [1] 2023 Novel Small Molecule FDA Drug Approvals. Blood 129(13): 1823-1830.

article thumbnail

Metabolism of 2022 FDA approved small molecule drugs PART 2

Metabolite Tales Blog

Metabolism of 2022 FDA approved small molecule drugs part 2 Mixing it Up By Julia Shanu-Wilson In Part 1 of this topic we looked at metabolism of the small molecule drugs approved by the FDA in 2022 that were mediated by CYP3A4. 8 This is not the only point of interest. We hope it was a useful two-parter!